BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day

BPL‑003 holds Breakthrough Therapy Designation and is supported by positive Phase 2b results in treatment-resistant depressionCash runway ...

AtaiBeckley outlines plans for Phase 3 trials of BPL-003 in treatment-resistant depression at Investor Day

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) highlighted progress across its clinical pipeline and reaffirmed its financial outlook during its 2026 Virtual Investor Day, outlining plans to advance its ...
The Manila Times

AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression

Aligned with FDA on dual-trial design Phase 3 program that aims to demonstrate robust efficacy and long-term safety and that allows for flexible dosingPhase 3 program initiation remains on track for ...
Nasdaq

atai Life Sciences Announces Positive Results from Phase 2a Study of BPL-003 for Treatment-Resistant Depression

Atai Life Sciences announced positive results from Beckley Psytech's Phase 2a study of BPL-003, an adjunctive treatment for patients with treatment-resistant depression (TRD) who are already on ...
Seeking Alpha

AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment ...

A 12 mg dose of BPL-003 (mebufotenin benzoate nasal spray) administered eight weeks after an initial 12 mg, 8 mg or 0.3 mg dose in the core study of the Phase 2b clinical trial produced additional ...